Strontium ranelate for postmenopausal osteoporosis;Le ranélate de strontium, nouvel agent thérapeutique dans l'ostéoporose post-ménopausique

Medecine/Sciences

Volumn 20, Issue 6-7, 2004, Pages 631-633

  Meunier, Pierre J ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

STRONTIUM; STRONTIUM RANELATE; UNCLASSIFIED DRUG;

BONE MINERALIZATION; BONE REMODELING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; HUMAN; MENOPAUSAL SYNDROME; NOTE; OSTEOPOROSIS;

EID: 3142760492     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2004206-7631     Document Type: Note

References (6)

1. Sharr E, Carter AC. The usefulness of strontium as an adjuvant to calcium in the remineralization of the skeleton in man. Bull Hosp Joint Dis 1952; 13: 59-66.
2. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001; 69: 121-9.
3. Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (5 12911) administration. J Bone Miner Res 1996; 9: 1302-11.
4. Meunier PJ, Slosman DD, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - A 2- year randomised placebo controlled trial. J Clin Endocrinal Metab 2002; 87: 2060-6.
5. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
6. Reginster JY, Sawicki A, Devogelaer JP, et al. Strontium ranelate reduces the risk of hip fracture in women with post-menopausal osteoporosis. Osteoporosis Int 2002; 13 (suppl 3): abstract 14.